...
首页> 外文期刊>European review for medical and pharmacological sciences. >Hepcidin protects pulmonary artery hypertension in rats by activating NF-κB/TNF-α pathway
【24h】

Hepcidin protects pulmonary artery hypertension in rats by activating NF-κB/TNF-α pathway

机译:肝素通过激活NF-κB/ TNF-α通路来保护大鼠肺动脉高血压

获取原文
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVE: The pulmonary artery hypertension (PAH) model was established in rats in this study. Therefore, we aimed to elucidate the protective role of Hepcidin in PAH rats and its underlying mechanism. MATERIALS AND METHODS: 24 male Sprague Dawley (SD) rats were randomly divided into sham group, PAH group and Hepcidin group, with 8 rats in each group. After animal procedures, hemodynamic parameters and right ventricular hypertrophy indexes were determined in rats. Cytokines in serum samples of rats were detected by enzyme-linked immunosorbent assay (ELISA). Pathological lesions in lung tissues were observed by hematoxylin and eosin (H&E) staining. Finally, Western blot was conducted to detect the protein expressions of nuclear factor-kappa B (NF-κB), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), vascular cell adhesion molecule 1 (VCAM-1), intercellular cell adhesion molecule-1 (ICAM-1), and monocyte chemotactic protein-1 (MCP-1) in lung tissues of rats. RESULTS: Compared with sham group, mean pulmonary artery pressure (mPAP) and right ventricular systolic pressure (RVSP) were significantly elevated in rats of PAH group (p0.05). On the contrary, mPAP and RVSP in rats of Hepcidin group were both significantly lower than PAH group (p0.05). Hepcidin treatment attenuated PAH-induced pathological lesions in lung tissues. ELISA results elucidated that Hepcidin treatment significantly decreased serum levels of TGF-β, TNF-α, IL-1β, and IL-6. In addition, Western blot results demonstrated that protein levels of NF-κB, TNF-α, IL-1β, VCAM-1, ICAM-1, and MCP-1 in Hepcidin group were remarkably lower than those of PAH group. CONCLUSIONS: Hepcidin alleviates inflammatory response in PAH rats by inhibiting NF-kB/ TNF-α pathway.
机译:目的:在本研究中的大鼠中建立了肺动脉高血压(PAH)模型。因此,我们旨在阐明肝素在PAH大鼠及其潜在机制中的保护作用。材料和方法:24只雄性Sprague Dawley(SD)大鼠随机分为假组,PAH组和肝素组,每组8只大鼠。在动物程序后,在大鼠中测定血液动力学参数和右心室肥厚指数。通过酶联免疫吸附试验(ELISA)检测大鼠血清样品中的细胞因子。通过苏木精和曙红(H&E)染色观察肺组织的病理病变。最后,进行蛋白质印迹以检测核因子-Kappa(NF-κB)的蛋白表达,肿瘤坏死因子-α(TNF-α),白细胞介素-1β(IL-1β),血管细胞粘附分子1(VCAM -1),大鼠肺组织中的细胞间粘附分子-1(ICAM-1)和单核细胞趋化蛋白-1(MCP-1)。结果:与假手术组相比,PAH组大鼠的平均肺动脉压(MPAP)和右心室收缩压(RVSP)显着升高(P <0.05)。相反,肝素组大鼠的MPAP和RVSP均明显低于PAH组(P <0.05)。肝素治疗减毒肺组织中的PAH诱导的病理病变。 ELISA结果阐明了肝素治疗显着降低了TGF-β,TNF-α,IL-1β和IL-6的血清水平。此外,Western印迹结果表明,Hepcidin组中NF-κB,TNF-α,IL-1β,VCAM-1,ICAM-1和MCP-1的蛋白质水平显着低于PAH组。结论:肝素通过抑制NF-KB / TNF-α通路来减轻PAH大鼠炎症反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号